Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coagulation01:06

Coagulation

983
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
983
Coagulation01:09

Coagulation

9.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

243
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
243
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.1K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

248
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
248

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of and Risk Factors for Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) After Pediatric Hematopoietic Stem Cell Transplantation for Hematological Malignancy: Protocol for a Cross-Sectional Cohort Study.

JMIR research protocols·2026
Same author

Between-centre variation in antibiotic therapeutic drug monitoring and obtaining surveillance cultures in Dutch ICUs: A retrospective observational study.

Journal of critical care·2026
Same author

Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK.

Endocrine connections·2026
Same author

Enhanced Nucleated Red Blood Cell Production but Ineffective Reticulocyte Differentiation in Preterm Growth-Restricted Infants.

International journal of laboratory hematology·2026
Same author

Factor XII locking in (for contact activation through disulfide control).

Journal of thrombosis and haemostasis : JTH·2026
Same author

Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.

British journal of clinical pharmacology·2026

Related Experiment Video

Updated: Dec 10, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K

A Pathophysiological Perspective on the SARS-CoV-2 Coagulopathy.

Nuray Kusadasi1, Maaike Sikma1,2, Albert Huisman3

  • 1Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.

Hemasphere
|September 5, 2020
PubMed
Summary

Patients with SARS-CoV-2 infection can experience a hypercoagulable state, leading to thromboembolic events. This review explores the complex interaction between coagulation and inflammation in severe COVID-19 coagulopathy.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

918
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

Related Experiment Videos

Last Updated: Dec 10, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

918
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

Area of Science:

  • Coagulation and Thrombosis
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Emerging evidence highlights a hypercoagulable state in SARS-CoV-2 infection.
  • This state is associated with both venous and arterial thromboembolic complications.
  • Coagulation activation correlates with disease severity, presenting as thrombotic microangiopathy and endotheliitis.

Purpose of the Study:

  • To review the interaction between coagulation and inflammation in SARS-CoV-2 infection.
  • To focus on potential mechanisms underlying COVID-19-associated coagulopathy in critically ill patients.

Main Methods:

  • Literature review of recent evidence on SARS-CoV-2 and coagulopathy.
  • Analysis of the interplay between inflammatory processes and coagulation pathways.
  • Discussion of pathomechanisms distinguishing COVID-19 coagulopathy from classical disseminated intravascular coagulation (DIC).

Main Results:

  • SARS-CoV-2 infection induces a prothrombotic state characterized by endotheliitis and thrombotic microangiopathy.
  • The observed coagulopathy differs from classical disseminated intravascular coagulation (DIC).
  • Inflammation significantly contributes to the dysregulation of coagulation in severe cases.

Conclusions:

  • COVID-19 is associated with a unique coagulopathy driven by the interaction of coagulation and inflammation.
  • Understanding these mechanisms is crucial for managing critically ill patients with SARS-CoV-2.
  • Further research into targeted anticoagulant and anti-inflammatory therapies is warranted.